Elanco Animal Company Leadership
| ELAN Stock | USD 13.40 0.04 0.30% |
Elanco Animal's insiders are aggressively buying. The analysis of insiders' sentiment of trading Elanco Animal Health stock suggests that virtually all insiders are extremely bullish at this time. Elanco Animal employs about 9.3 K people. The company is managed by 38 executives with a total tenure of roughly 123 years, averaging almost 3.0 years of service per executive, having 244.74 employees per reported executive.
| Jeffrey Simmons CEO President, Chief Executive Officer, Director |
| Sarena Lin President Executive Vice President, Global Marketing, Corporate Strategy and Transformation |
Elanco Animal's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-08-22 | Michael J Harrington | Acquired 3500 @ 14.85 | View | ||
| 2024-08-12 | Jeffrey N Simmons | Acquired 100000 @ 13.01 | View | ||
| 2024-05-21 | William F Doyle | Acquired 15000 @ 16.98 | View | ||
| 2024-03-06 | R David Hoover | Acquired 20000 @ 16.14 | View |
Monitoring Elanco Animal's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Elanco |
Elanco Animal's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Elanco Animal's future performance. Based on our forecasts, it is anticipated that Elanco will maintain a workforce of about 9300 employees by December 2024.Elanco Animal's latest congressional trading
Congressional trading in companies like Elanco Animal Health, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Elanco Animal by those in governmental positions are based on the same information available to the general public.
| 2024-10-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-07-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2022-06-30 | Representative Alan S Lowenthal | Acquired Under $15K | Verify | ||
| 2020-07-17 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
| 2019-03-23 | Representative Alan S Lowenthal | Acquired Under $15K | Verify |
Elanco Animal Management Team Effectiveness
The company has return on total asset (ROA) of 0.0118 % which means that it generated a profit of $0.0118 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0324 %, meaning that it created $0.0324 on every $100 dollars invested by stockholders. Elanco Animal's management efficiency ratios could be used to measure how well Elanco Animal manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Capital Employed is likely to grow to 0.03, though Return On Tangible Assets are likely to grow to (0.24). As of the 21st of November 2024, Asset Turnover is likely to grow to 0.33, while Total Assets are likely to drop about 13.6 B.As of the 21st of November 2024, Common Stock Shares Outstanding is likely to drop to about 447.6 M. In addition to that, Net Loss is likely to drop to about (73.7 M)
Elanco Animal Workforce Comparison
Elanco Animal Health is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 132,150. Elanco Animal holds roughly 9,300 in number of employees claiming about 7% of equities under Health Care industry.
Elanco Animal Profit Margins
The company has Profit Margin (PM) of 0.05 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.42 | 0.5628 |
|
| |||||
| Operating Profit Margin | 0.0542 | 0.0738 |
|
|
Elanco Animal Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elanco Animal insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elanco Animal's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Elanco Animal insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 7.5 | 15 | 2 | 109,381 | 5,505 |
| 2024-06-01 | 8.0 | 16 | 2 | 19,563 | 31,066 |
| 2024-03-01 | 1.92 | 48 | 25 | 1,584,158 | 267,610 |
| 2023-12-01 | 7.0 | 14 | 2 | 229,072 | 11,295 |
| 2023-09-01 | 1.6667 | 5 | 3 | 34,491 | 4,107 |
| 2023-06-01 | 4.0 | 4 | 1 | 115,452 | 7,508 |
| 2023-03-01 | 1.2857 | 36 | 28 | 2,356,551 | 403,028 |
| 2022-12-01 | 21.0 | 21 | 1 | 219,386 | 11,295 |
| 2022-09-01 | 8.5 | 17 | 2 | 74,571 | 4,040 |
| 2022-03-01 | 1.9 | 38 | 20 | 1,030,213 | 190,023 |
| 2021-12-01 | 4.0 | 28 | 7 | 154,928 | 26,873 |
| 2021-09-01 | 8.5 | 17 | 2 | 41,395 | 3,358 |
| 2021-06-01 | 13.0 | 13 | 1 | 28,989 | 70.00 |
| 2021-03-01 | 1.28 | 32 | 25 | 342,433 | 106,514 |
| 2020-12-01 | 2.25 | 18 | 8 | 90,415 | 54,554,956 |
| 2020-09-01 | 5.0 | 10 | 2 | 75,919 | 7,058 |
| 2020-03-01 | 1.3333 | 20 | 15 | 245,018 | 56,459 |
| 2019-12-01 | 2.0 | 14 | 7 | 55,245 | 57,085 |
| 2019-03-01 | 24.0 | 24 | 1 | 567,666 | 293,290,000 |
| 2018-09-01 | 11.0 | 11 | 1 | 72,825 | 0.00 |
Elanco Animal Notable Stakeholders
An Elanco Animal stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Elanco Animal often face trade-offs trying to please all of them. Elanco Animal's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Elanco Animal's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jeffrey Simmons | President, Chief Executive Officer, Director | Profile | |
| Sarena Lin | Executive Vice President, Global Marketing, Corporate Strategy and Transformation | Profile | |
| David Kinard | Executive Vice President, Human Resources, Corporate Affairs and Administration | Profile | |
| David Urbanek | Executive Vice President - Manufacturing, Quality | Profile | |
| Aaron Schacht | Executive Vice President, Innovation, Regulatory and Business Development | Profile | |
| James Meer | Senior Vice President, Chief Accounting Officer | Profile | |
| Shiv ONeill | General President | Profile | |
| Todd Young | Chief Financial Officer, Executive Vice President | Profile | |
| Ramiro Cabral | Executive Vice President - Elanco International and Global Customer Value | Profile | |
| Todd JD | Executive CFO | Profile | |
| Joshua Smiley | Independent Director | Profile | |
| Carl McMillian | Independent Director | Profile | |
| Denise ScotsKnight | Independent Director | Profile | |
| Kirk McDonald | Independent Director | Profile | |
| Art Garcia | Independent Director | Profile | |
| Kapila Anand | Independent Director | Profile | |
| Michael Harrington | Independent Director | Profile | |
| David Ricks | Independent Director | Profile | |
| Deborah Kochevar | Independent Director | Profile | |
| Lawrence Kurzius | Independent Director | Profile | |
| Aarti Shah | Independent Director | Profile | |
| William Doyle | Independent Director | Profile | |
| John Bilbrey | Independent Director | Profile | |
| Jose Simas | Executive Vice President U.S. Farm Animal Business | Profile | |
| Timothy Bettington | Executive Development | Profile | |
| Chris Keeley | Senior Officer | Profile | |
| Katy Grissom | Head Relations | Profile | |
| Ellen Brabander | Executive Vice President - Innovation and Regulatory Affairs | Profile | |
| Paul Herendeen | Independent Director | Profile | |
| Racquel Mason | Executive Vice President and Chief Marketing Officer, Elanco Animal Health | Profile | |
| Rajeev Modi | Executive Vice President - U.S. Pet Health and Global Digital Transformation | Profile | |
| R Hoover | Independent Chairman of the Board | Profile | |
| Larbi Lier | Senior Asia | Profile | |
| Joyce Lee | Executive Vice President and President U.S. Pet Health and Commercial Operations | Profile | |
| Marcela Kirberger | Executive Vice President General Counsel, Company Secretary | Profile | |
| Scott Ferguson | Independent Director | Profile | |
| Shawn McKee | Sr Animal | Profile | |
| Dirk Ehle | Executive Vice President and President Elanco Europe | Profile |
About Elanco Animal Management Performance
The success or failure of an entity such as Elanco Animal Health often depends on how effective the management is. Elanco Animal management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Elanco management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Elanco management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.24) | |
| Return On Capital Employed | 0.02 | 0.03 | |
| Return On Assets | (0.09) | (0.08) | |
| Return On Equity | (0.20) | (0.19) |
Elanco Animal Workforce Analysis
Traditionally, organizations such as Elanco Animal use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Elanco Animal within its industry.Elanco Animal Manpower Efficiency
Return on Elanco Animal Manpower
| Revenue Per Employee | 474.9K | |
| Revenue Per Executive | 116.2M | |
| Net Loss Per Employee | 132.4K | |
| Net Loss Per Executive | 32.4M | |
| Working Capital Per Employee | 232.9K | |
| Working Capital Per Executive | 57M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elanco Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elanco Animal. If investors know Elanco will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elanco Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.71) | Earnings Share 0.41 | Revenue Per Share 9.023 | Quarterly Revenue Growth (0.04) | Return On Assets 0.0118 |
The market value of Elanco Animal Health is measured differently than its book value, which is the value of Elanco that is recorded on the company's balance sheet. Investors also form their own opinion of Elanco Animal's value that differs from its market value or its book value, called intrinsic value, which is Elanco Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elanco Animal's market value can be influenced by many factors that don't directly affect Elanco Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elanco Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Elanco Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elanco Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.